EPO-Eluting Biopolymer Matrix for Crushed Peripheral Nerve Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for crushed peripheral nerve injuries, particularly moderate to severe cases, face challenges in accelerating motor and sensory function recovery, protecting neurons and Schwann cells from degeneration, improving myelination, and increasing the number of myelinated axons across the injury site.
Innovation Solution
An implantable drug-delivery device composed of a biopolymer matrix that entraps erythropoietin (EPO), which elutes over a controlled period from 1 day to 12 weeks, providing a protective and regenerative environment for injured nerves by promoting axonal growth and myelination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If spontaneous recovery is observed in mild crush injury, then functional recovery occurs naturally, but the recovery time is extended and functional outcome is limited
Solution Approach 1:
The patent applies preliminary action by administering erythropoietin (EPO) before complete nerve degeneration occurs. The drug is delivered to the injury site within a critical time window (first few days to weeks) to prevent neuronal death and initiate regenerative processes before irreversible damage occurs, thereby accelerating recovery while improving functional outcomes
Solution Approach 2:
The patent changes the biochemical parameter environment at the injury site by introducing EPO, which alters the local concentration of neuroprotective factors. This parameter change triggers cascading biological responses including reduced apoptosis, enhanced axonal growth, and improved myelination, thereby accelerating functional recovery without extending time loss
2Reliability
If surgery is performed for severe crush injury, then nerve continuity is restored, but complete motor function recovery is not achieved and neuropathic pain persists
Solution Approach 1:
The patent uses erythropoietin as an intermediary substance that mediates between the surgical repair and functional recovery. EPO acts as a biochemical bridge that enhances the outcomes of surgical intervention by promoting neuronal survival, axonal regeneration, and myelination, thereby achieving more complete motor function recovery and reducing neuropathic pain that would otherwise persist after surgery
Solution Approach 2:
The patent employs a composite approach by combining surgical mechanical repair with biochemical therapy. The delivery device itself is a composite structure (biodegradable polymer matrix containing EPO) that provides both structural support and pharmacological action, creating a synergistic effect that improves motor function recovery and eliminates neuropathic pain more effectively than surgery alone
3Reliability
If EPO is administered to protect neurons and Schwann cells, then cell survival improves, but the delivery mechanism becomes complex requiring controlled release over time
Solution Approach 1:
The patent applies self-service by using a biodegradable polymer delivery device that automatically releases EPO over time without requiring external intervention. The device degrades naturally in the body, providing sustained drug delivery through its degradation kinetics, thereby simplifying the overall system while maintaining effective cell protection
Solution Approach 2:
The patent uses a porous biodegradable polymer matrix as the delivery vehicle. The porous structure allows controlled diffusion of EPO from the matrix to the surrounding tissue, providing sustained release without complex mechanical components. The porosity and degradation rate are engineered to match the therapeutic timeline needed for nerve regeneration and cell protection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The EPO-eluting device enhances nerve repair by protecting neurons, accelerating myelination, and improving functional recovery, effectively addressing the limitations of existing treatments for crushed peripheral nerve injuries.
Implementation Method 1
the EPO elutes over a period of 1 day to 12 weeks
Implementation Method 2
The matrix mentioned above is semipermeable and is formed of a biopolymer
Data Source
AI summary
An implantable drug-delivery device for repairing a crushed peripheral nerve. The drug-delivery device includes a matrix formed of a biopolymer and an erythropoietin (EPO) entrapped in the matrix. After in vivo implantation of the drug-delivery device, the EPO elutes over a period of 1 day to 12 weeks. Also disclosed is a method for repairing a crushed peripheral nerve using the implantable drug-delivery device.